References
- Ministero della Sanita. Bollettino Epidemiologico. Available from: URL: http://www.sanita.it/sanita/malinf/ BollEpid/illnes_all/.
- Centers for Diseases Control and Prevention. Brucellosis. Available from: URL: http://www.cdc.gov/nci-dod/dbmd/diseaseinfo/brucellosis_t.htm
- Young EJ. An overview of human brucellosis. Clin Infec Dis 1995; 21 (2): 283–290.
- Hall WH Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1990; 12 (6): 1060-1099.
- Joint Food and Agriculture Organization, World Health Organization. FAO-WHO Expert Committee on brucellosis. 6th report. WHO Technical Report Series, no. 740. WHO Geneva 1986.
- Solera J, Rodriguez-Zapata M, Geijo P et al. Doxycycline-rifampin versus doxycycline-streptomycin in treat-ment of human brucellosis due to BruceIla melitensis. Antimicrob Agents Chemother 1995; 39 (9): 2061-2067.
- Lubani MM, Dudin KI, Sharda DC et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J 1989; 8 (2): 75-78.
- Street MAJL Jr, Grant WW, Alva JD. Brucellosis in childhood. Pediatrics 1975; 55 (3): 416–421.
- Llorens-Terol J, Busquests RM. Brucellosis treated with rifampin. Arch Dis Child 1980; 55 (6): 486–488.
- Kelly RG, Kanegis LA. Metabolism and tissue distribu-tion of radioisotopically labeled minocycline. Toxicol Appl Pharmacol 1967; 11 (1): 171–183.
- Di Nola F, Soranzo ML. Terapia della brucellosi. Min Med 1986; 77 (37): 1647–1662.
- Rubinstein E, Lang R, Shasha B et al. In vitro suscepti-bility of BruceIla melitensis to antibiotics. Antimicrob Agents Chemother 1991; 35 (9): 1925-1927.
- Gutierrez Altes A, Diez Enciso M, Pena Garcia P, Campos Bueno A. In vitro activity of N-formidoyl thienamyvin against 98 clinical isolates of BruceIla melitensis compared with those of cefoxitin, rifampicin, tetracycline and cotrimoxa-zole. Antimicrob Agents Chemother 1982; 21 (3): 501–503.
- Young EJ. Brucella species. In: Yu VL, Merigan TC Jr, Barriere S (eds): Antimicrobial therapy and vaccines. William & Wilkins, Baltimore 1999: 71-89.
- Akova M, Gtir D, Livermore DM Kocagoz T, Akalin HE. In vitro activities of antibiotics alone and in combination against BruceIla melitensis at neutral and acidic pHs. Antimicrob Agents Chemother 1999; 43 (5): 1298–1300.
- Kornfeld S, Mellman I. The biogenesis of lysosomes. Annu Rev Cell Biol 1989; 5: 483–525
- Farr BM. Rifamycins. In: Mandell GL, Bennett JE, Dolin R (eds): Principles and practice of infectious diseases. 5th ed. Churchill Livingstone, Philadelphia 2000; 348-361.
- Standiford HC. Tetracyclines and Chloramphenicol. In: Mandell GL, Bennett JE, Dolin R (eds): Principles and practice of infectious diseases. 5th ed. Churchill Livingstone, Philadelphia 2000; 336-348.
- Aygen B, Dogitanay M, Stimerkan B,. Yildiz O, Kayabas U. Clinical manifestations, complications and treat-ment of brucellosis: a retrospective evaluation of 480 patients. Med Mal Infect 2002; 32: 485–493
- Fisen D, Hakim MD. Minocycline-induced pigmenta-tion. Incidence, prevention and management. Drug Safety 1998; 18 (6): 431–440.
- American Academy of Pediatrics. Rocky Mountain spotted fever. In: Peter G (ed): Red Book. Report of the com-mittee on infectious diseases. 24th ed. American Academy of Pediatrics, Elk Grove Village, IL 2000; 452-454.
- Grasso E, Conversa P, Mondino P, Spirolazzi MP, Dalmasso G, Raineri G. Su 295 casi di brucellosi trattati con minociclina. Min Med 1987; 78 (19): 1443–1447.